237 related articles for article (PubMed ID: 32395869)
1. CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
Chen Y; Tang J; Lu T; Liu F
Thorac Cancer; 2020 Jul; 11(7):1848-1860. PubMed ID: 32395869
[TBL] [Abstract][Full Text] [Related]
2. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
[TBL] [Abstract][Full Text] [Related]
3. BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment.
Wang F; Zhang L; Sai B; Wang L; Zhang X; Zheng L; Tang J; Li G; Xiang J
Cancer Biol Ther; 2020; 21(1):61-71. PubMed ID: 31559898
[TBL] [Abstract][Full Text] [Related]
4. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival.
Jin T; Li D; Yang T; Liu F; Kong J; Zhou Y
Oncol Rep; 2019 Aug; 42(2):717-725. PubMed ID: 31173266
[TBL] [Abstract][Full Text] [Related]
5. GALNT2 promotes cell proliferation, migration, and invasion by activating the Notch/Hes1-PTEN-PI3K/Akt signaling pathway in lung adenocarcinoma.
Wang W; Sun R; Zeng L; Chen Y; Zhang N; Cao S; Deng S; Meng X; Yang S
Life Sci; 2021 Jul; 276():119439. PubMed ID: 33785338
[TBL] [Abstract][Full Text] [Related]
6. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.
Zhu HE; Yin JY; Chen DX; He S; Chen H
Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997
[TBL] [Abstract][Full Text] [Related]
7. Actin-like protein 8 promotes cell proliferation, colony-formation, proangiogenesis, migration and invasion in lung adenocarcinoma cells.
Ma S; Wang X; Zhang Z; Liu D
Thorac Cancer; 2020 Mar; 11(3):526-536. PubMed ID: 31962007
[TBL] [Abstract][Full Text] [Related]
8. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
9. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
10. LncRNA LINC00511 promotes COL1A1-mediated proliferation and metastasis by sponging miR-126-5p/miR-218-5p in lung adenocarcinoma.
Wang Y; Mei X; Song W; Wang C; Qiu X
BMC Pulm Med; 2022 Jul; 22(1):272. PubMed ID: 35842617
[TBL] [Abstract][Full Text] [Related]
11. Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC.
Wang J; Zhou P; Wang X; Yu Y; Zhu G; Zheng L; Xu Z; Li F; You Q; Yang Q; Zhuo W; Sun J; Chen Z
Cell Prolif; 2019 May; 52(3):e12592. PubMed ID: 30848009
[TBL] [Abstract][Full Text] [Related]
12. NSUN2 promotes lung adenocarcinoma progression through stabilizing PIK3R2 mRNA in an m
Du X; Cheng C; Yang Y; Fan B; Wang P; Xia H; Ni X; Liu Q; Lu L; Wei L
Mol Carcinog; 2024 May; 63(5):962-976. PubMed ID: 38411298
[TBL] [Abstract][Full Text] [Related]
13. Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy.
Hsieh MS; Lin MW; Lee YH
Lung Cancer; 2019 Nov; 137():76-84. PubMed ID: 31561203
[TBL] [Abstract][Full Text] [Related]
14. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
Park HS; Lee DH; Kang DH; Yeo MK; Bae G; Lee D; Yoo G; Kim JO; Moon E; Huh YH; Lee SH; Jo EK; Cho SY; Lee JE; Chung C
Cancer Med; 2021 Feb; 10(4):1405-1417. PubMed ID: 33486901
[TBL] [Abstract][Full Text] [Related]
15. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
[TBL] [Abstract][Full Text] [Related]
16. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
Fong JT; Jacobs RJ; Moravec DN; Uppada SB; Botting GM; Nlend M; Puri N
PLoS One; 2013; 8(11):e78398. PubMed ID: 24223799
[TBL] [Abstract][Full Text] [Related]
17. IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.
Hussmann D; Madsen AT; Jakobsen KR; Luo Y; Sorensen BS; Nielsen AL
Oncotarget; 2017 May; 8(20):33300-33315. PubMed ID: 28418902
[TBL] [Abstract][Full Text] [Related]
18. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
[TBL] [Abstract][Full Text] [Related]
19. miR-9-5p Promotes Lung Adenocarcinoma Cell Proliferation, Migration and Invasion by Targeting ID4.
Zhu K; Lin J; Chen S; Xu Q
Technol Cancer Res Treat; 2021; 20():15330338211048592. PubMed ID: 34723712
[No Abstract] [Full Text] [Related]
20. CircPRKCI regulates proliferation, migration and cycle of lung adenocarcinoma cells by targeting miR-219a-5p-regulated CAMK1D.
Sui MH; Zhang WW; Geng DM; Sun DJ
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1899-1909. PubMed ID: 33660800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
